Endometrial Cancer Trial, Recruiting NCT06771193 Sponsor: MSD Italia S.r.l. Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06771193
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The patient (or their legal representative) must have signed and dated the required consent and privacy form.
  • The person must be 18 years of age or older.
  • The person must have a diagnosis of cervical cancer.
  • The cancer must be either locally advanced (meaning surgery to cure is not suitable), or it has come back, or it has spread to other parts of the body.
  • The person must have received some form of treatment for advanced cervical cancer between January 2018 and December 2021.

Who may not be able to join:

  • People who are currently participating in another clinical trial involving medications for advanced cervical cancer.
  • People who have previously participated in any clinical trial (confirm with trial site).
  • People who have previously been given Pembrolizumab, Olaparib, or Levantinib, or any medications belonging to the same drug families as these.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39 03626331

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
MSD Italia S.r.l.
Registry
ClinicalTrials.gov
Start date
17 December 2024
Est. completion
1 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

The proportion of patients receiving each different treatment pattern of LA, recurrent, and metastatic CC (%); The proportion of patient with recurrence or dead after treatment and remission (%); Median time from remission to recurrence; Number of lines of treatment; The costs in terms of resources utilization associated to the different treatment patterns of LA, recurrent and metastatic CC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov